American biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991 as Incyte Pharmaceuticals and listed on Nasdaq, with European operations in Morges, Switzerland and Japanese operations in Tokyo. Discovers, develops and markets small molecule and biologic medicines in oncology and inflammation and autoimmunity, including the JAK inhibitors ruxolitinib and its topical form, pemigatinib, retifanlimab and axatilimab, and runs its own research organisation and global clinical development.
No hay comentarios disponibles.
Deja tu valoración & comentario